# A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.

> **NCT07429721** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 24 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** QI-019A Injection

## Key facts

- **NCT ID:** NCT07429721
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07429721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07429721, "A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07429721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*